1033 related articles for article (PubMed ID: 23590898)
41. Comparative activity of tigecycline and tetracycline on Gram-negative and Gram-positive bacteria revealed by a multicentre study in four North European countries.
Nilsson LE; Frimodt-Møller N; Vaara M; Simonsen GS;
Scand J Infect Dis; 2011 Sep; 43(9):707-13. PubMed ID: 21619494
[TBL] [Abstract][Full Text] [Related]
42. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline.
Reinert RR; Low DE; Rossi F; Zhang X; Wattal C; Dowzicky MJ
J Antimicrob Chemother; 2007 Nov; 60(5):1018-29. PubMed ID: 17855724
[TBL] [Abstract][Full Text] [Related]
43. Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010.
Hawser SP; Bouchillon SK; Hackel M; Chen M; Kim EC
Int J Antimicrob Agents; 2012 Jun; 39(6):490-5. PubMed ID: 22534507
[TBL] [Abstract][Full Text] [Related]
44. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C;
Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645
[TBL] [Abstract][Full Text] [Related]
45. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
Zhanel GG; DeCorby M; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; Mulvey MR; Hoban DJ;
Diagn Microbiol Infect Dis; 2008 Sep; 62(1):67-80. PubMed ID: 18513913
[TBL] [Abstract][Full Text] [Related]
46. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study.
Rossolini GM; Dryden MS; Kozlov RS; Quintana A; Flamm RK; Läuffer JM; Lee E; Morrissey I; CLASS Study Group
J Antimicrob Chemother; 2011 Jan; 66(1):151-9. PubMed ID: 21051375
[TBL] [Abstract][Full Text] [Related]
47. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals.
Souli M; Kontopidou FV; Koratzanis E; Antoniadou A; Giannitsioti E; Evangelopoulou P; Kannavaki S; Giamarellou H
Antimicrob Agents Chemother; 2006 Sep; 50(9):3166-9. PubMed ID: 16940120
[TBL] [Abstract][Full Text] [Related]
48. Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.
Hoban DJ; Reinert RR; Bouchillon SK; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2015 May; 14():27. PubMed ID: 25958201
[TBL] [Abstract][Full Text] [Related]
49. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
50. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 Jun; 76(2):217-21. PubMed ID: 23522845
[TBL] [Abstract][Full Text] [Related]
51. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008).
Farrell DJ; Turnidge JD; Bell J; Sader HS; Jones RN
J Infect; 2010 Jun; 60(6):440-51. PubMed ID: 20361999
[TBL] [Abstract][Full Text] [Related]
52. Etiology, extended-spectrum β-lactamase rates and antimicrobial susceptibility of gram-negative bacilli causing intra-abdominal infections in patients in general pediatric and pediatric intensive care units--global data from the Study for Monitoring Antimicrobial Resistance Trends 2008 to 2010.
Badal RE; Bouchillon SK; Lob SH; Hackel MA; Hawser SP; Hoban DJ
Pediatr Infect Dis J; 2013 Jun; 32(6):636-40. PubMed ID: 23838732
[TBL] [Abstract][Full Text] [Related]
53. Bacterial susceptibility in bloodstream infections: Results from China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2015-2016.
Zhang F; Li Y; Lv Y; Zheng B; Xue F
J Glob Antimicrob Resist; 2019 Jun; 17():276-282. PubMed ID: 30611932
[TBL] [Abstract][Full Text] [Related]
54. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
Nagy E; Dowzicky MJ
Scand J Infect Dis; 2010; 42(1):33-8. PubMed ID: 19883155
[TBL] [Abstract][Full Text] [Related]
55. [Multicenter study of in vitro activity of tigecycline in clinical isolates from 30 centers in Spain].
García-Rodríguez JA;
Rev Esp Quimioter; 2009 Jun; 22(2):76-82. PubMed ID: 19554486
[TBL] [Abstract][Full Text] [Related]
56. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
Denys GA; Koch KM; Dowzicky MJ
Am J Infect Control; 2007 Oct; 35(8):521-6. PubMed ID: 17936143
[TBL] [Abstract][Full Text] [Related]
57. Antimicrobial susceptibility among bacterial isolates from ICU and non-ICU setting and different age groups: results from the tigecycline evaluation and Surveillance trial in North America.
Low DE; Markovic MJ; Dowzicky MJ
J Chemother; 2009 Feb; 21(1):16-23. PubMed ID: 19297267
[TBL] [Abstract][Full Text] [Related]
58. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
Korten V; Ulusoy S; Zarakolu P; Mete B;
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):453-7. PubMed ID: 17888609
[TBL] [Abstract][Full Text] [Related]
59. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; López F; Alvarez J; Picazo JJ;
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):437-44. PubMed ID: 16949245
[TBL] [Abstract][Full Text] [Related]
60. [Analysis of resistance tendency of bloodstream-infecting pathogens in China].
Lü Y; Li Y; Xue F; Zhang XZ; Hu YJ; Jin YF; Chu YZ; Hu ZD; Zhao JH; Pan SY; Zhao WS; Hu BJ; Yu YS; Deng QL; Yang J; Li Y; Liu WE; Lü XJ; Yang YJ; Zhou L; Dong F; Fu WL; Xu XL; Pei FY; Yang B; Meng L; Ji P; Wang S
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jun; 36(6):411-9. PubMed ID: 24103203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
